Agnieszka Cieplinska Net Worth

The estimated Net Worth of Agnieszka Cieplinska is at least 486 千$ dollars as of 29 June 2020. Agnieszka Cieplinska owns over 947 units of Momenta Pharmaceuticals stock worth over 397,484$ and over the last 5 years Agnieszka sold MNTA stock worth over 88,824$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Agnieszka Cieplinska MNTA stock SEC Form 4 insiders trading

Agnieszka has made over 3 trades of the Momenta Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently Agnieszka sold 947 units of MNTA stock worth 33,249$ on 29 June 2020.

The largest trade Agnieszka's ever made was selling 947 units of Momenta Pharmaceuticals stock on 29 June 2020 worth over 33,249$. On average, Agnieszka trades about 562 units every 16 days since 2020. As of 29 June 2020 Agnieszka still owns at least 7,574 units of Momenta Pharmaceuticals stock.

You can see the complete history of Agnieszka Cieplinska stock trades at the bottom of the page.

What's Agnieszka Cieplinska's mailing address?

Agnieszka's mailing address filed with the SEC is C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Momenta Pharmaceuticals

Over the last 20 years, insiders at Momenta Pharmaceuticals have traded over 110,027,424$ worth of Momenta Pharmaceuticals stock and bought 827,300 units worth 5,505,611$ . The most active insiders traders include Christoph H Westphal、Craig A Wheeler、Peter Barrett. On average, Momenta Pharmaceuticals executives and independent directors trade stock every 6 days with the average trade being worth of 448,442$. The most recent stock trade was executed by Ian Fier on 20 August 2020, trading 1,808 units of MNTA stock currently worth 94,323$.

What does Momenta Pharmaceuticals do?

Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.

Complete history of Agnieszka Cieplinska stock trades at Momenta Pharmaceuticals

Momenta Pharmaceuticals executives and stock owners

Momenta Pharmaceuticals executives and other stock owners filed with the SEC include:

• Donna Roy Grogan,
  Director
• Jose Carlos Gutierrez Ramos,
  Director
• Santiago Arroyo,
  SVP, Chief Medical Officer
• Craig A Wheeler,
  President & CEO
• Corey N. Fishman,
  Director
• Marsha Fanucci,
  Director
• James R Sulat,
  Director
• Bruce Leicher,
  SVP & General Counsel
• Matthew P. Ottmer,
  Chief Operating Officer
• Richard P Shea,
  VP, Chief Financial Officer
• Georges Gemayel,
  Director
• Thomas P Koestler,
  Director
• Steven C Gilman,
  Director
• Bruce Downey,
  Director
• Elizabeth Stoner,
  Director
• Scott M Storer,
  SVP, CFO
• James M. Roach,
  Senior VP, Development and Chi
• Michelle Robertson,
  Chief Financial Officer
• Anthony M. Manning,
  Chief Scientific Officer
• Jo Ann Beltramello,
  Chief HR and Inf. Officer
• Alejandra Carvajal,
  Chief Legal Officer
• Ian Fier,
  Chief Mfg and Program Officer
• Young Kwon,
  Chief Financial & Bus. Officer
• Peter Barrett,
  Director
• Peter Barton Hutt,
  Director
• Paul D Goldenheim,
  Director
• Stephen B Brugger,
  VP, Strategic Prod Devl.
• John L Zabriskie,
  Director
• Ram Sasisekharan,
  Director
• Venture Management Co Iii L...,
  
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Bennett M Shapiro,
  Director
• Stephen T Reeders,
  Director
• International Life Sciences...,
  10% owner
• Ganesh Venkataraman,
  VP, Technology
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Michael Franken,
  President, Biosimilars Busines
• Robert Langer,
  Director
• Carron Shmerling Lisa,
  V.P., Legal Affairs
• John E Bishop,
  VP Pharma Sciences & Manufact
• Susan K Whoriskey,
  VP, Licensing and Bus. Develop
• Alan L Crane,
  President and CEO
• Venture Fund V Lpatlas Vent...,
  
• John K Clarke,
  Director
• Jane F Barlow,
  Director
• Agnieszka Cieplinska,
  Chief Accounting Officer (PAO)